What Happened: The 2023 Restrictions
In late 2023, the FDA placed 19 widely used peptides onto its Category 2 list — a classification that effectively prohibited licensed compounding pharmacies from preparing and dispensing them. The list included BPC-157, TB-500, GHK-Cu (injectable), Selank, Semax, and others.
The FDA's Category system governs bulk drug substances in compounding. Category 1 substances have enough documented safety history for compounders to use. Category 2 means the substance presents unacceptable risk for compounding. The 2023 designations were contested — compounding industry groups challenged them in court, arguing the FDA bypassed required notice-and-comment procedures.
For researchers and the broader peptide community, the result was a significant reduction in legitimately sourced product through clinical channels. Research peptide vendors operating under "for research use only" frameworks remained active throughout.
The 2026 Reversal
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr., appearing on episode #2461 of the Joe Rogan Experience, announced that approximately 14 of the 19 restricted peptides would move back toward Category 1 status. BPC-157 was named among them.
On April 15, 2026, HHS formally confirmed removal of 12 peptides from Category 2. On April 22, 2026, BPC-157 and TB-500 were officially removed from the restricted list.
Removal from Category 2 is not the same as Category 1 approval. Each substance requires individual PCAC review and formal FDA rulemaking before compounding pharmacies may legally prepare them. As of today, BPC-157 is in a regulatory gap between the two categories.
The Regulatory Timeline
What's on the July 23 Agenda
The FDA's Federal Register notice confirmed these seven compounds for PCAC evaluation at the July 23–24 hearing:
| Peptide | Use Cases Under Review | Session |
|---|---|---|
| BPC-157 free base & acetate |
Ulcerative colitis, tissue repair, gut health | Day 1 · Jul 23 |
| TB-500 Thymosin Beta-4 fragment |
Wound healing, cell migration, musculoskeletal repair | Day 1 · Jul 23 |
| KPV | Anti-inflammatory, gut mucosal repair | Day 1 · Jul 23 |
| MOTS-c | Metabolic regulation, mitochondrial function | Day 1 · Jul 23 |
| Semax | Cerebral ischemia, cognitive function, migraine | Day 2 · Jul 24 |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | Day 2 · Jul 24 |
| Epitalon | Telomere support, longevity research | Day 2 · Jul 24 |
Note: GHK-Cu (injectable) and Selank are not on the July agenda. The FDA has announced GHK-Cu will be reviewed at a separate PCAC meeting before February 2027.
What This Means for Researchers Right Now
Research Vendors Are Not Affected
The FDA's compounding pharmacy framework governs prescription-based clinical use. Research peptide vendors — selling products labeled for research use only, not for human consumption — operate outside this framework. BPC-157 has been continuously available through US research suppliers throughout the 2023–2026 restriction period and remains available today.
Evo Peptides carries BPC-157, TB-500, Semax, Selank, GHK-Cu, NAD+, and Bacteriostatic Water — all products relevant to researchers following this regulatory story. Every product is third-party tested with a COA on file.
A Positive Vote Doesn't Mean Immediate Clinical Access
Even if the PCAC votes favorably on July 23, the process doesn't end there. The PCAC is advisory — it makes recommendations, not binding decisions. The FDA must then initiate formal rulemaking before compounding pharmacies can legally prepare BPC-157 with prescriptions. This takes additional time with no fixed timeline.
A positive July vote will be the biggest peptide regulatory story of 2026 — but researchers should not expect same-day compounding pharmacy availability after the hearing.
Context: The 2024 PCAC Vote Was Negative
A previous PCAC hearing in 2024 resulted in the committee voting against inclusion of all peptides under review, citing unacceptable safety risks. The political environment has shifted significantly since then under the current HHS posture, but a favorable outcome in July is not guaranteed.